Elena Tonti

Elena Tonti

Auto-generated profile, based on publicly available information

Elena Tonti

McMaster University

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2010 in Nature
Verified
Journal Article
Open access
PDF file
MIMatteo Iannacone
Matteo Iannacone
EME. Ashley Moseman
E. Ashley Moseman
ETElena Tonti
Elena Tonti
LBLidia Bosurgi
Lidia Bosurgi
TJTobias Junt
Tobias Junt
UAUlrich H. von Andrian
Ulrich H. von Andrian
Microorganisms that breach the body's external defences and enter the lymphatic system are liable to be captured by the lymph nodes, and recent work showed that a subset of macrophages found in the subcapsular sinus (SCS) of lymph nodes is critical for clearance of viruses from the lymph and for initiating antiviral humoral immune responses. Now a third function for SCS macrophages has been identified: the prevention of lymph-borne neurotropic viruses from infecting the CNS. Using vesicular stomatitis virus (VSV) as a model, Iannacone et al. showed that local depletion of SCS macrophages made mice injected subcutaneously with VSV more vulnerable to the virus via a mechanism dependent on type I interferon. VSV is a relative of rabies virus typically transmitted by insect bites, causing a fatal paralytic disease in some mammals. Combined with further experiments in mice lacking the IFN-I receptor, these findings suggest that SCS macrophages are crucial gatekeepers to the CNS that prevent fatal viral neuroinvasion upon peripheral infection. Macrophages that populate the lymph nodes are known to clear viruses from the lymph and to initiate antiviral humoral immune responses. It is now shown that these macrophages also have another function: they prevent lymph-borne neurotropic viruses from entering the central nervous system. The mechanism is dependent on the production of type I interferon. Lymph nodes (LNs) capture microorganisms that breach the body’s external barriers and enter draining lymphatics, limiting the systemic spread of pathogens1. Recent work has shown that CD11b+CD169+ macrophages, which populate the subcapsular sinus (SCS) of LNs, are critical for the clearance of viruses from the lymph and for initiating antiviral humoral immune responses2,3,4. Here we show, using vesicular stomatitis virus (VSV), a relative of rabies virus transmitted by insect bites, that SCS macrophages perform a third vital function: they prevent lymph-borne neurotropic viruses from infecting the central nervous system (CNS). On local depletion of LN macrophages, about 60% of mice developed ascending paralysis and died 7–10 days after subcutaneous infection with a small dose of VSV, whereas macrophage-sufficient animals remained asymptomatic and cleared the virus. VSV gained access to the nervous system through peripheral nerves in macrophage-depleted LNs. In contrast, within macrophage-sufficient LNs VSV replicated preferentially in SCS macrophages but not in adjacent nerves. Removal of SCS macrophages did not compromise adaptive immune responses against VSV, but decreased type I interferon (IFN-I) production within infected LNs. VSV-infected macrophages recruited IFN-I-producing plasmacytoid dendritic cells to the SCS and in addition were a major source of IFN-I themselves. Experiments in bone marrow chimaeric mice revealed that IFN-I must act on both haematopoietic and stromal compartments, including the intranodal nerves, to prevent lethal infection with VSV. These results identify SCS macrophages as crucial gatekeepers to the CNS that prevent fatal viral invasion of the nervous system on peripheral infection.

6 March 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GGGrazia Galli
Grazia Galli
PPPaola Pittoni
Paola Pittoni
ETElena Tonti
Elena Tonti
CMCarmine Malzone
Carmine Malzone
YUYasushi Uematsu
Yasushi Uematsu
SASergio Abrignani
Sergio Abrignani
Invariant natural killer T (iNKT) cells are innate-like lymphocytes recognizing CD1d-restricted glycolipid antigens, such as α-galactosylceramide (αGC). We assessed whether iNKT cells help B lymphocyte responses and found that mice immunized with proteins and αGC develop antibody titers 1–2 logs higher than those induced by proteins alone. Activation of iNKT cells enhances protection against infections such as influenza and elicits higher frequencies of memory B cells and higher antibody responses to booster immunizations. Protein vaccination with αGC, but not with conventional adjuvants, elicits IgG responses in mice lacking MHC class II molecules, demonstrating that iNKT cells can substitute for CD4+T cell help to B cells. Interestingly, the decay of circulating antibodies is faster in mice lacking iNKT cells. These findings point to a homeostatic role for iNKT cells on critical features of the antibody response such as immunity and B cell memory.

1 May 2014 in Vaccine
Verified
Journal Article
Open access
PIPetr O. Ilyinskii
Petr O. Ilyinskii
CRChristopher J. Roy
Christopher J. Roy
COConlin P. O’neil
Conlin P. O’neil
EBErica A. Browning
Erica A. Browning
LPLynnelle A. Pittet
Lynnelle A. Pittet
TKTakashi Kei Kishimoto
Takashi Kei Kishimoto
Augmentation of immunogenicity can be achieved by particulate delivery of an antigen and by its co-administration with an adjuvant. However, many adjuvants initiate strong systemic inflammatory reactions in vivo, leading to potential adverse events and safety concerns. We have developed a synthetic vaccine particle (SVP) technology that enables co-encapsulation of antigen with potent adjuvants. We demonstrate that co-delivery of an antigen with a TLR7/8 or TLR9 agonist in synthetic polymer nanoparticles results in a strong augmentation of humoral and cellular immune responses with minimal systemic production of inflammatory cytokines. In contrast, antigen encapsulated into nanoparticles and admixed with free TLR7/8 agonist leads to lower immunogenicity and rapid induction of high levels of inflammatory cytokines in the serum (e.g., TNF-a and IL-6 levels are 50- to 200-fold higher upon injection of free resiquimod (R848) than of nanoparticle-encapsulated R848). Conversely, local immune stimulation as evidenced by cellular infiltration of draining lymph nodes and by intranodal cytokine production was more pronounced and persisted longer when SVP-encapsulated TLR agonists were used. The strong local immune activation achieved using a modular self-assembling nanoparticle platform markedly enhanced immunogenicity and was equally effective whether antigen and adjuvant were co-encapsulated in a single nanoparticle formulation or co-delivered in two separate nanoparticles. Moreover, particle encapsulation enabled the utilization of CpG oligonucleotides with the natural phosphodiester backbone, which are otherwise rapidly hydrolyzed by nucleases in vivo. The use of SVP may enable clinical use of potent TLR agonists as vaccine adjuvants for indications where cellular immunity or robust humoral responses are required.

1 November 2011 in Cell
Verified
Journal Article
Closed access
NCNicolas Chevrier
Nicolas Chevrier
PMPhilipp Mertins
Philipp Mertins
MAMaxim N. Artyomov
Maxim N. Artyomov
ASAlex K. Shalek
Alex K. Shalek
MIMatteo Iannacone
Matteo Iannacone
NHNir Hacohen
Nir Hacohen

1 March 2012 in Immunity
Verified
Journal Article
Closed access
EME. Ashley Moseman
E. Ashley Moseman
MIMatteo Iannacone
Matteo Iannacone
LBLidia Bosurgi
Lidia Bosurgi
ETElena Tonti
Elena Tonti
NCNicolas Chevrier
Nicolas Chevrier
UAUlrich H. von Andrian
Ulrich H. von Andrian

1 April 2012 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ETElena Tonti
Elena Tonti
MFMaya Fedeli
Maya Fedeli
ANAnna Napolitano
Anna Napolitano
MIMatteo Iannacone
Matteo Iannacone
UAUlrich H. von Andrian
Ulrich H. von Andrian
PDPaolo Dellabona
Paolo Dellabona
B cells require MHC class II (MHC II)-restricted cognate help and CD40 engagement by CD4+ T follicular helper (TFH) cells to form germinal centers and long-lasting Ab responses. Invariant NKT (iNKT) cells are innate-like lymphocytes that jumpstart the adaptive immune response when activated by the CD1d-restricted lipid α-galactosylceramide (αGalCer). We previously observed that immunization of mice lacking CD4+ T cells (MHC II−/−) elicits specific IgG responses only when protein Ags are mixed with αGalCer. In this study, we investigated the mechanisms underpinning this observation. We find that induction of Ag-specific Ab responses in MHC II−/− mice upon immunization with protein Ags mixed with αGalCer requires CD1d expression and CD40 engagement on B cells, suggesting that iNKT cells provide CD1d-restricted cognate help for B cells. Remarkably, splenic iNKT cells from immunized MHC II−/− mice display a typical CXCR5hiprogrammed death-1hiICOShiBcl-6hi TFH phenotype and induce germinal centers. The specific IgG response induced in MHC II−/− mice has shorter duration than that developing in CD4-competent animals, suggesting that iNKTFH cells preferentially induce transient rather than long-lived Ab responses. Together, these results suggest that iNKT cells can be co-opted into the follicular helper function, yet iNKTFH and CD4+ TFH cells display distinct helper features, consistent with the notion that these two cell subsets play nonredundant functions throughout immune responses.